Lung Cancer Diagnostic and Screening Market is Estimated to Witness High Growth Owing to Increasing Investments in Development of Noninvasive Diagnostic Techniques
Lung Cancer Diagnostic and Screening Market |
Lung cancer diagnostic and screening involves identification of abnormalities or cancer in the lungs through various imaging techniques and biomarkers. Computed Tomography (CT) scans and low-dose computed tomography (LDCT) are commonly used for lung cancer screening as they can detect small nodules in the lungs at an early stage. Moreover, advances in genetic biomarkers, molecular testing, and imaging techniques are facilitating noninvasive diagnosis and better screening of lung cancer.
The Global Lung Cancer Diagnostic and Screening Market is estimated to be
valued at US$ 2243.98 Mn in 2023 and is expected to exhibit a CAGR of 42.% over
the forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Market Opportunity:
There is significant opportunity for growth in the lung cancer diagnostic and
screening market owing to increasing investments by companies as well as
governments for development of noninvasive diagnostic techniques. Noninvasive
diagnosis methods reduces the need for invasive biopsy procedures. Researchers
are focusing on development of blood tests, breath analysis, and imaging
methods like PET scans that can detect cancer at an early stage from blood or
breath samples noninvasively. This reduces the risk, cost, and trauma of lung
biopsy for patients. Growing demand for early and noninvasive diagnosis is
expected to drive market growth over the forecast period.
Porter's Analysis
Threat of new entrants: The lung cancer diagnostic and screening market
requires large scale R&D investments and well established distribution channels
limiting threat of new entrants.
Bargaining power of buyers: Buyers have moderate bargaining power due to
availability of substitutes however differentiated products and services limit
impact on pricing.
Bargaining power of suppliers: Suppliers have low to moderate bargaining power
due to availability of substitutes and differentiated inputs required.
Threat of new substitutes: Threat of substitutes is low as lung cancer
diagnostics requires specialized expertise and technology.
Competitive rivalry: The market sees intense competition due to strategic
partnerships and technological innovations.
SWOT Analysis
Strength: Advanced technologies such as imaging, pathology and fluid analysis
enable accurate diagnosis. Growing reimbursement and initiatives increase
access and adoption.
Weakness: High capital requirements and costs limit access in low income
regions. Shortage of skilled professionals poses challenges.
Opportunity: Rising incident of lung cancer due to smoking and pollution
presents opportunities. Untapped potential in developing countries.
Threats: Stringent regulations increase compliance cost. Reimbursement cuts and
policy changes impact revenues.
Key Takeaways
Global
Lung Cancer Diagnostic and Screening Market Insights is expected to witness
high growth on account of increasing incidence of lung cancer cases worldwide.
Market is estimated to be valued at US$ 2243.98 Mn in 2023 and is expected to
exhibit a CAGR of 42.% over the forecast period 2023 to 2030.
Comments
Post a Comment